Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NVP-VAK694 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| NVP-VAK694 | DRUG | - |
Inclusion Criteria: * History of allergic rhinitis (Part 2 only) Exclusion Criteria: * Very low or high body weight * Heavy or recent smoker * Exposure to human monoclonal antibodies Other protocol-defined inclusion/exclusion criteria may apply.
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE3 | LY3650150, Standard therapy for INCS |
| Polyrizon Ltd. | PLRZ | 1 | N/A | Undisclosed |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | - | Undisclosed |
NVP-VAK694 is an investigational small molecule being developed for allergic rhinitis. It is a respiratory therapeutic that has completed a Phase 1 clinical trial. The drug is not approved and remains in clinical development.
NVP-VAK694 is being developed by Novartis AG, which trades under the ticker NVS. The company conducted a Phase 1 trial of the drug in the United States.
NVP-VAK694 is in Phase 1 clinical development. It has completed one Phase 1 trial, and no active trials are currently listed. The drug is investigational and not yet approved.
NVP-VAK694 has one completed clinical trial, NCT00620230, titled "Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects." The trial enrolled 46 participants in the United States and was a randomized, double-blind, placebo-controlled study.
Yes, NVP-VAK694 is also known as VAK694. The clinical trial NCT00620230 refers to the drug as VAK694, and it is being studied for allergic rhinitis.